Moderna Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Moderna non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-0.4%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-0.4%
Rendimento futuro dei dividendi	0%
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Nov 22

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Oct 22

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Oct 11

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27

Moderna: Counting On Pipeline Too Much

Feb 23

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di MRNA siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di MRNA siano aumentati.

Rendimento dei dividendi rispetto al mercato

Moderna Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di MRNA rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (MRNA)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.2%
Media del settore (Biotechs)	2.3%
Analista previsionale (MRNA) (fino a 3 anni)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di MRNA rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di MRNA rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di MRNA per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché MRNA non ha segnalato alcun pagamento.

Moderna Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Price target decreased by 7.3% to US$85.05

Price target decreased by 7.0% to US$85.80

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna: Still Bullish View

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Price target decreased by 16% to US$105

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Consensus revenue estimates fall by 21%

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Moderna, Inc. Announces Board Changes

Co-Founder notifies of intention to sell stock

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna: Really Strong Competition

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Co-Founder notifies of intention to sell stock

Moment Of Truth Approaches For Moderna's RSV Vaccine

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

Moderna Q1: A Promising Pipeline Is Undervalued

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Moderna: Considering The Cancer Vaccine Angle

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna Continues To Build A Pipeline

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Co-Founder notifies of intention to sell stock

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

President notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Moderna: Counting On Pipeline Too Much

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti